Industry News
News and Press Releases
Psyence Group Corporate Update
Psyence Group Corporate Update
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical Program TORONTO, May 31, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise in the manufacture of pharmaceutical grade [...]
Psyence Group Announces DTC Eligibility Approval in the U.S
TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.
News and Press Releases
Psyence Group Corporate Update
Psyence Group Corporate Update
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical Program TORONTO, May 31, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise in the manufacture of pharmaceutical grade [...]
Psyence Group Announces DTC Eligibility Approval in the U.S
TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.
Psyence In The News
Psyence wins ISO certification from British Standards Institute for psilocybin production facility
Psyence Group Inc’s Yasin Khan tells Proactive the life science biotechnology company’s psilocybin production facility has officially received International Organization for Standardization (ISO) 22000:2018 certification through the British Standards Institute (BSI).
ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems. Psyence’s facility, which is federally licensed to cultivate and export Psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
Psyence Group’s functional mushroom brand to be sold in South Africa’s largest coffee retail chain
Psyence Group begins trading on the OTCQB platform in New York to satisfy investor demand
Psyence Group Inc CFO Warwick Corden-Lloyd joined Proactive New York to discuss the group’s plan to increase exposure to US investors by beginning to trade on the OTCQB Venture Market platform. In addition, the Toronto-based firm said it has applied for Depository Trust Company (DTC) eligibility to simplify the trading process in the US. Corden-Lloyd says Psyence will have a presence at two upcoming conferences to discuss its recent advancements: the “The End in Mind – Psychedelic Medicines & Ending Well” and “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms.”
Psyence Group launches its functional mushroom products under the GOODMIND banner in South Africa
Psyence Group Inc (CSE:PSYG)’s Tony Budden caught up with Proactive New York to discuss the the international biotechnology company with operations in South Africa’s launch of its range of functional mushroom products under the GOODMIND banner.
In this interview with Proactive Investors, Dr. Neil Maresky talks about his appointment as CEO of Psyence Group.
He shares insights about his career, including spending more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky, a South African trained doctor, tells Proactive about his motivation to join Psyence, stating that it is because of its ability to potentially impact mental health including depression, anxiety, PTSD, and end-of-life care.
Take a listen here.
Psyence Group ‘delighted’ to reach psilocybin product development agreement with Jamaican government
Interested in Psyence’s collaboration with the Jamaican government’s Scientific Research Council (SRC)? Take a listen to the Proactive Investors interview with Psyence CEO Jody Aufrichtig and learn more about the agreement which will consist of three key initiatives: developing psilocybin-based nutraceuticals; identifying and collecting Jamaica’s psychedelic and psychoactive mushrooms, and sorting protocols to optimize spawn production of rare psychedelic mushroom species.
Psychedelic Finance chats to Psyence CEO Jody Aufrichtig
19 January 2021
Find out why our CEO believes in psychedelics, what Psyence stands for and how the lessons Jody learnt in the cannabis industry are helping him navigate the psychedelics opportunity in this in depth Q&A with Psychedelic Finance.
Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller
19 February 2021
Psyence joined the CSE’s Barrington Miller to tell our story and share what we believe sets Psyence apart from other companies in this space: we are licensed, operational and global. Want to know more?
Take a look at this video: